GlycoMimetics (GLYC) Tops Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. CDNS
2. AVGO
3. JBLU
4. ANT
5. META
6. SSD
7. AGYS
8. PECO
9. AMKR
10. BX

Go back to GlycoMimetics (GLYC) Tops Q2 EPS by 8c

GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments

November 7, 2019 8:24 AM EST

Advanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sponsored clinical trials Announced abstracts accepted for presentation in December at the Annual Meeting of the American Society of Hematology (ASH) in Orlando, which continue to demonstrate key role of E-selectin ligand and potential value of uproleselan in AML Announced that Pfizers Phase 3 clinical trial evaluating rivipansel in sickle cell disease (SCD) failed to meet the primary endpoint and key secondary endpoints Eliminated certain non-core research and development spending commitments

... More